Nippon Life Global Investors Americas Inc. Has $4.44 Million Holdings in Zoetis Inc. $ZTS

Nippon Life Global Investors Americas Inc. decreased its stake in Zoetis Inc. (NYSE:ZTS) by 13.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,320 shares of the company’s stock after selling 4,540 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in Zoetis were worth $4,436,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC raised its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the last quarter. REAP Financial Group LLC raised its holdings in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. NewSquare Capital LLC raised its holdings in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. ORG Partners LLC lifted its position in shares of Zoetis by 56.8% in the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after acquiring an additional 84 shares during the period. Finally, Financial Consulate Inc. acquired a new stake in shares of Zoetis during the 3rd quarter worth approximately $39,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $124.79 on Friday. The business’s fifty day moving average is $123.21 and its two-hundred day moving average is $139.49. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The firm has a market cap of $54.99 billion, a P/E ratio of 21.01, a P/E/G ratio of 2.53 and a beta of 0.97. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is currently 35.69%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent research reports. Barclays assumed coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Stifel Nicolaus dropped their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday, December 18th. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research report on Wednesday, December 10th. Six research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.